AVCRF Avricore Health Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1355736 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2023Q4*2023-12-31 | 2023Q3*2023-09-30 | 2023Q2*2023-06-30 | 2022Q4*2022-12-31 | 2022Q3*2022-09-30 | 2022Q2*2022-06-30 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1.35M | 953,454 | 522,156 | 977,235 | 572,228 | 176,175 |
| Cost of revenue | 852,937 | 691,676 | 318,578 | 808,390 | 356,267 | 119,301 |
| Gross profit | 501,466 | 261,778 | 229,471 | 168,845 | 215,961 | 56,874 |
| SG&A expense | 73,211 | 79,720 | 101,780 | 58,809 | 84,434 | 73,032 |
| Net income | 59,584 | -285,062 | -284,225 | -244,789 | -180,398 | -207,363 |
| EPS (basic) | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
| EPS (diluted) | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | — | 99.64M | 99.63M | — | 97.70M | 97.70M |
| Balance sheet | ||||||
| Cash & equivalents | 276,571 | 389,531 | 472,371 | 620,527 | 869,129 | 1.44M |
| Receivables | 427,689 | 461,147 | 213,513 | 770,373 | — | — |
| Inventory | 20,676 | — | — | — | — | — |
| Current assets | 773,561 | 916,978 | 754,642 | 1.43M | — | — |
| PP&E, netmay include right-of-use assets (IFRS) | 1.72M | 1.50M | 1.36M | 1.11M | — | — |
| Intangibles | — | 32,459 | 33,829 | 29,861 | — | — |
| Total assets | 2.54M | 2.45M | 2.14M | 2.57M | — | — |
| Current liabilities | — | 646,498 | 356,438 | 604,893 | — | — |
| Total liabilities | 529,218 | 646,498 | 356,438 | 604,893 | — | — |
| Shareholders' equity | 2.01M | 1.81M | 1.79M | 1.96M | 1.75M | 1.86M |
| Cash flow statement | ||||||
| Operating cash flow | 248,003 | 184,568 | — | -24,272 | 19,821 | — |
| Capital expenditure | 343,326 | 267,241 | — | 429,210 | 607,759 | — |
| Free cash flow | -95,323 | -82,673 | — | -453,482 | -587,938 | — |
| Investing cash flow | -360,963 | -267,408 | — | -439,210 | -610,193 | — |
| Financing cash flow | 0 | 0 | — | 214,880 | 15,000 | — |
| Depreciation & amortization | 587 | 667 | 781 | -104,386 | 75,373 | 22,065 |
| Stock-based compensation | 142,765 | 304,328 | 168,518 | 243,000 | 58,354 | 9,069 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.